232 related articles for article (PubMed ID: 23329364)
1. New insights into the genetics of neuroblastoma.
Sridhar S; Al-Moallem B; Kamal H; Terrile M; Stallings RL
Mol Diagn Ther; 2013 Apr; 17(2):63-9. PubMed ID: 23329364
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma progress on many fronts: the Neuroblastoma Research Symposium.
Wylie L; Philpott A
Pediatr Blood Cancer; 2012 Apr; 58(4):649-51. PubMed ID: 21922652
[TBL] [Abstract][Full Text] [Related]
4. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
Bagci O; Tumer S; Olgun N; Altungoz O
Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
[TBL] [Abstract][Full Text] [Related]
5. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.
Zhu S; Lee JS; Guo F; Shin J; Perez-Atayde AR; Kutok JL; Rodig SJ; Neuberg DS; Helman D; Feng H; Stewart RA; Wang W; George RE; Kanki JP; Look AT
Cancer Cell; 2012 Mar; 21(3):362-73. PubMed ID: 22439933
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.
Owens C; Irwin M
Crit Rev Clin Lab Sci; 2012; 49(3):85-115. PubMed ID: 22646747
[TBL] [Abstract][Full Text] [Related]
7. New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.
Barone G; Anderson J; Pearson AD; Petrie K; Chesler L
Clin Cancer Res; 2013 Nov; 19(21):5814-21. PubMed ID: 23965898
[TBL] [Abstract][Full Text] [Related]
8. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.
Bachetti T; Di Paolo D; Di Lascio S; Mirisola V; Brignole C; Bellotti M; Caffa I; Ferraris C; Fiore M; Fornasari D; Chiarle R; Borghini S; Pfeffer U; Ponzoni M; Ceccherini I; Perri P
PLoS One; 2010 Oct; 5(10):. PubMed ID: 20957039
[TBL] [Abstract][Full Text] [Related]
9. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
[TBL] [Abstract][Full Text] [Related]
10. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
[TBL] [Abstract][Full Text] [Related]
11. ALK pERKs up MYCN in neuroblastoma.
Lindner S; Henssen A; Astrahantseff K; Schulte JH
Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
[TBL] [Abstract][Full Text] [Related]
12. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
13. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
Schulte JH; Lindner S; Bohrer A; Maurer J; De Preter K; Lefever S; Heukamp L; Schulte S; Molenaar J; Versteeg R; Thor T; Künkele A; Vandesompele J; Speleman F; Schorle H; Eggert A; Schramm A
Oncogene; 2013 Feb; 32(8):1059-65. PubMed ID: 22484425
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma: developmental biology, cancer genomics and immunotherapy.
Cheung NK; Dyer MA
Nat Rev Cancer; 2013 Jun; 13(6):397-411. PubMed ID: 23702928
[TBL] [Abstract][Full Text] [Related]
16. The MYCN oncogene and differentiation in neuroblastoma.
Westermark UK; Wilhelm M; Frenzel A; Henriksson MA
Semin Cancer Biol; 2011 Oct; 21(4):256-66. PubMed ID: 21849159
[TBL] [Abstract][Full Text] [Related]
17. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
[TBL] [Abstract][Full Text] [Related]
18. Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.
Passariello A; De Brasi D; Defferrari R; Genesio R; Tufano M; Mazzocco K; Capasso M; Migliorati R; Martinsson T; Siani P; Nitsch L; Tonini GP
Eur J Med Genet; 2013 Nov; 56(11):626-34. PubMed ID: 24035971
[TBL] [Abstract][Full Text] [Related]
19. Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncology.
Schwab M
Ann N Y Acad Sci; 2002 Jun; 963():63-73. PubMed ID: 12095930
[TBL] [Abstract][Full Text] [Related]
20. Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.
Villamón E; Berbegall AP; Piqueras M; Tadeo I; Castel V; Djos A; Martinsson T; Navarro S; Noguera R
PLoS One; 2013; 8(1):e53740. PubMed ID: 23341988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
